In this study, among IESS patients in the hypsarrhythmia subgroup, those with higher baseline serum levels of IGF-1, IGFBP-3, and their ratio prior to treatment demonstrated a significantly better response to ACTH therapy. The gene discussed is IGFBP3; the disease is Hypsarrhythmia.